The amended Company Law of China (the New Company Law) took effect on July 1, 2024, making substantial changes to existing rules in a wide range of areas including, among others, new timeline requirements for capital...more
China’s main healthcare regulatory bodies, including the National Medical Products Administration, released draft administrative measures for pharmaceutical representatives intended to strengthen anti-corruption efforts and...more
China’s National Medical Products Administration (NMPA) on November 13, 2024 issued the Interim Provisions on the Administration of the Domestic Responsible Person Designated by Foreign Marketing Authorization Holders (New...more